European Journal of Cancer最新文献

{"title":"Unraveling the clinical impact of differential DNA methylation in PDAC: A systematic review","authors":"Julia Adriana Kasmirski,&nbsp;Raj Roy,&nbsp;Christopher Wu,&nbsp;Lauren Wheeler,&nbsp;K. Kerrick Akinola,&nbsp;Herbert Chen,&nbsp;J. Bart Rose,&nbsp;Changde Cheng,&nbsp;Smita Bhatia,&nbsp;Andrea Gillis","doi":"10.1016/j.ejca.2025.115384","DOIUrl":"10.1016/j.ejca.2025.115384","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite significant efforts to improve clinical outcomes, pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate. The poor prognosis associated with this disease is multifactorial and associated with a highly variable genetic profile associated with its pathogenesis. Epigenetic modifications including DNA methylation further affect the expression of genetic material. However, there is no comprehensive understanding of the clinical impact of DNA methylation in PDAC.</div></div><div><h3>Methods</h3><div>A systematic literature review was registered on the International Prospective Register of Systematic Reviews database (CRD42023451955) and followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. An electronic search was conducted using the following databases: CINAHL Plus, Cochrane Library, Embase, Web of Science, Ovid Medline, and Google Scholar. Inclusion criteria included studies of patients with a PDAC diagnosis and information regarding genes or CpG sites that potentially affect diagnosis, prognosis, or survival of PDAC.</div></div><div><h3>Results</h3><div>The initial search retrieved 2402 articles, and 423 duplicates were excluded. After exclusion criteria was applied, 19 studies were included. The most common genes recorded as affecting tumor pathogenesis were <em>SFRP1</em> (n = 3/19, 15.7 %) and <em>NPTX2</em> (n = 2/19, 10,5 %). Studies indicated that hypermethylation of <em>SFRP1</em> and <em>NPTX2</em> were associated with poor prognosis.</div></div><div><h3>Conclusions</h3><div>PDAC is associated with a range of epigenetic modifications. Methylation of specific genes related to PDAC may influence survival and prognosis and be a therapeutic target. Individual patient epigenetic analysis may be a future direction in directing PDAC treatment and prognosis.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115384"},"PeriodicalIF":7.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial","authors":"Paolo Bossi ,&nbsp;Andrea Alberti ,&nbsp;Cristiana Bergamini ,&nbsp;Carlo Resteghini ,&nbsp;Laura Deborah Locati ,&nbsp;Salvatore Alfieri ,&nbsp;Stefano Cavalieri ,&nbsp;Elena Colombo ,&nbsp;Cristina Gurizzan ,&nbsp;Luigi Lorini ,&nbsp;Valeria Tovazzi ,&nbsp;Manuel Zamparini ,&nbsp;Marco Ravanelli ,&nbsp;Paolo Antonio Ascierto ,&nbsp;Vittorio Rampinelli ,&nbsp;Alberto Grammatica ,&nbsp;Roberto Patuzzo ,&nbsp;Andrea Maurichi ,&nbsp;Lisa Francesca Licitra","doi":"10.1016/j.ejca.2025.115379","DOIUrl":"10.1016/j.ejca.2025.115379","url":null,"abstract":"<div><h3>Background</h3><div>Immunotherapy with pembrolizumab and cemiplimab achieves an overall response rate (ORR) of 34–51 % in locally advanced/metastatic (LA/M) cSCC, but primary and acquired resistance remains a challenge. This study evaluates whether adding cetuximab to pembrolizumab can overcome resistance by reducing immune escape.</div></div><div><h3>Patients and methods</h3><div>I-TACKLE is a phase II, open-label trial conducted at three Italian centers. Patients received intravenous pembrolizumab 200 mg every 3 weeks, and cetuximab was added in cases of stable disease or progression. The primary endpoint was cumulative ORR by a single agent or by combination strategy. Secondary endpoints included safety, progression-free survival (PFS), overall survival (OS), and response duration.</div></div><div><h3>Results</h3><div>From May 2019 to April 2021, 43 patients were enrolled and treated with pembrolizumab, and 23 received combination therapy. Median treatment durations were 3 months (pembrolizumab) and 4 months (combination). Cumulative ORR was 63 % [95 % CI 48–77], with 19/43 (44 %) responding to pembrolizumab and 8/21 (38 %) responding to the combination after resistance. Both patients experiencing an acquired resistance to pembrolizumab obtained partial response when cetuximab was introduced. Overall, 10/23 (44 %) responded to the combination. One-year PFS was 51 % with pembrolizumab and 42 % with combination therapy. Grade 3–4 treatment-related adverse events occurred in 7/43 (16 %) during pembrolizumab and 8/23 (35 %) during combination therapy, primarily dermatitis (30 %).</div></div><div><h3>Conclusions</h3><div>In LA/M cSCC, the addition of cetuximab to pembrolizumab reverts primary and acquired resistance with manageable toxicities. This sequential approach warrants further study.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115379"},"PeriodicalIF":7.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study","authors":"Jason J. Luke ,&nbsp;Paolo A. Ascierto ,&nbsp;Muhammad A. Khattak ,&nbsp;Piotr Rutkowski ,&nbsp;Michele Del Vecchio ,&nbsp;Francesco Spagnolo ,&nbsp;Jacek Mackiewicz ,&nbsp;Luis de la Cruz Merino ,&nbsp;Vanna Chiarion-Sileni ,&nbsp;John M. Kirkwood ,&nbsp;Caroline Robert ,&nbsp;Dirk Schadendorf ,&nbsp;Federica de Galitiis ,&nbsp;Matteo S. Carlino ,&nbsp;Reinhard Dummer ,&nbsp;Peter Mohr ,&nbsp;Amos Odeleye-Ajakaye ,&nbsp;Mizuho Fukunaga-Kalabis ,&nbsp;Clemens Krepler ,&nbsp;Alexander M.M. Eggermont ,&nbsp;Georgina V. Long","doi":"10.1016/j.ejca.2025.115381","DOIUrl":"10.1016/j.ejca.2025.115381","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB/IIC melanoma in KEYNOTE-716. Results of a post hoc 4-year analysis are reported, including progression/recurrence-free survival 2 (PRFS2).</div></div><div><h3>Methods</h3><div>Patients were randomly assigned 1:1 to pembrolizumab 200 mg or placebo intravenously every 3 weeks (part 1). RFS was the primary end point; DMFS was secondary. Patients with recurrence following placebo or 17 cycles of pembrolizumab could cross over to or be rechallenged with pembrolizumab (part 2).</div></div><div><h3>Results</h3><div>Median follow-up (n = 976) was 52.8 months (range, 39.4–64.8). RFS (HR, 0.62 [95 % CI, 0.50–0.78]) and DMFS (HR, 0.59 [0.45–0.77]) favored pembrolizumab. At 48 months, RFS rates were 71.3 % for pembrolizumab and 58.3 % for placebo, and DMFS rates were 81.0 % and 70.1 %, respectively. The HR for PRFS2 was 0.75 (95 % CI, 0.56–1.01); 48-month PRFS2 rates were 82.5 % for pembrolizumab and 76.7 % for placebo. In the crossover population, median follow-up was 36.9 months; median RFS was not reached (NR; 95 % CI, 16.8-NR; 48-month RFS, 50.6 %) in patients with resectable disease (n = 41) and median progression-free survival was 22.0 months (4.5-NR) in patients with unresectable disease (n = 30). Among patients rechallenged, median follow-up was 21.9 months; none with resectable disease had recurrence (n = 6) and 1 with unresectable disease had best response of stable disease (n = 3). No new safety signals were observed.</div></div><div><h3>Conclusions</h3><div>With &gt; 4 years follow-up, pembrolizumab continued to prolong RFS and DMFS and had antitumor activity in patients who crossed over to pembrolizumab.</div><div>Trial registration: NCT03553836</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115381"},"PeriodicalIF":7.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines","authors":"Loïc Renaud ,&nbsp;Marie Donzel ,&nbsp;Justine Decroocq ,&nbsp;Pierre Decazes ,&nbsp;Jean Galtier ,&nbsp;Barbara Burroni ,&nbsp;Elena-Liana Veresezan ,&nbsp;Côme Sesboüé ,&nbsp;Peggy Dartigues ,&nbsp;Catherine Chassagne-Clément ,&nbsp;Laurent Martin ,&nbsp;Claire Mauduit ,&nbsp;Sophie Kaltenbach ,&nbsp;Dominique Penther ,&nbsp;Pascaline Etancelin ,&nbsp;David Sibon ,&nbsp;Sarah Bailly ,&nbsp;Valentine Martin ,&nbsp;Eric Durot ,&nbsp;Youlia Kirova ,&nbsp;Vincent Camus","doi":"10.1016/j.ejca.2025.115369","DOIUrl":"10.1016/j.ejca.2025.115369","url":null,"abstract":"<div><div>Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma with unique clinical, histopathological, and molecular characteristics. Despite its aggressive nature, PMBCL has a high cure rate when managed appropriately. Advances in the understanding of PMBCL biological characteristics, coupled with improvements in diagnostic tools and therapeutic approaches, have significantly improved patient outcomes in recent years. In this article, we present a set of pragmatic guidelines developed by the Lymphoma Study Association (LYSA) for the management of PMBCL. These guidelines address key aspects of diagnosis, staging, response evaluation, and treatment, integrating the latest evidence from clinical trials, expert consensus, and real-world practice. The aim of the guidelines is to provide clinicians with a clear, practical framework to optimize care for patients with PMBCL, ensuring that the best available evidence is translated into clinical practice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115369"},"PeriodicalIF":7.6,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of accelerated infusion of nivolumab and pembrolizumab","authors":"Loes van Rijssen ,&nbsp;Iris E.C. Nagtegaal ,&nbsp;Floortje K. Ploos van Amstel ,&nbsp;Chantal M.L. Driessen ,&nbsp;Nielka P. van Erp ,&nbsp;Anja Timmer-Bonte ,&nbsp;Sarah R. Verhoeff","doi":"10.1016/j.ejca.2025.115373","DOIUrl":"10.1016/j.ejca.2025.115373","url":null,"abstract":"<div><div>Nivolumab and pembrolizumab are checkpoint inhibitors targeting programmed cell death-1, used for several types of cancer. The increased use of these drugs and the growing number of cancer patients place a significant burden on the hospital ward capacity. Safely reducing the infusion time of immune checkpoint inhibitors could improve capacity. The aim of this implementation project was to explore the safety of accelerated infusion time for nivolumab and pembrolizumab. Patients who received monotherapy nivolumab or pembrolizumab were included in the implementation project. The administration time according to label of nivolumab and pembrolizumab was reduced over 2–3 treatment cycles from 60 and 30–10 min. Vital signs were measured every 15 min from start until 30 min after completion of each administration. If a hypersensitivity reaction (HSR) occurred, infusion was interrupted, and its severity was graded. Between January 2023 and December 2024, 101 patients were enrolled (316 infusions). This included 72 patients with nivolumab and 29 with pembrolizumab treatment. Only grade 1 and 2 HSR were observed. In total 11 HSRs were observed during the administration of nivolumab. Nine HSRs occurred during the 30-minute and two during the 10-minute infusion. No HSR was recorded with pembrolizumab. The accelerated infusion of nivolumab and pembrolizumab in 10 min is safe and results in considerable time efficiency. This strategy is potentially feasible for more immune checkpoint inhibitors and should therefore be considered to facilitate the treatment of the increasing number of cancer patients.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115373"},"PeriodicalIF":7.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T cell therapy for patients with extramedullary multiple myeloma：Opportunities and challenges","authors":"Yin Wang ,&nbsp;Xiaoli Hu ,&nbsp;Juan Du ,&nbsp;Bei Liu","doi":"10.1016/j.ejca.2025.115374","DOIUrl":"10.1016/j.ejca.2025.115374","url":null,"abstract":"<div><div>Multiple myeloma (MM) is a hematological malignancy characterized by abnormal proliferation of clonal plasma cells, which is usually confined to the bone marrow (BM). But some malignant plasma cells grow independently of the BM, called extramedullary disease (EMD). With the clinical application of proteasome inhibitors, immunomodulators, monoclonal antibodies, and hematopoietic stem cell transplantation, the overall survival of MM patients has been significantly improved, but the survival of patients with EMD is still worse than that of non-EMD patients. There are currently no specific treatment options for EMD. chimeric antigen receptor T (CAR-T) cell therapy has brought a new era of immunotherapy. The application of CAR-T has significantly benefited many MM patients, and CAR-T may be a new hope for patients with EMD in the future. This review retrospectively summarizes the mechanism and prognosis of EMD, focusing on the application and potential of CAR-T in the treatment of EMD. It is hoped that this review can provide ideas for the treatment of EMD with CAR-T in the future.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115374"},"PeriodicalIF":7.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial","authors":"G. Eminowicz ,&nbsp;S. Vaja ,&nbsp;D. Gallardo ,&nbsp;C. Kent ,&nbsp;M. Panades ,&nbsp;T. Mathew ,&nbsp;A. Anand ,&nbsp;J. Forrest ,&nbsp;M. Adusumalli ,&nbsp;A. Chan ,&nbsp;A.M. Hacker ,&nbsp;A. Hackshaw ,&nbsp;J.A. Ledermann ,&nbsp;M. McCormack","doi":"10.1016/j.ejca.2025.115375","DOIUrl":"10.1016/j.ejca.2025.115375","url":null,"abstract":"<div><h3>Aim</h3><div>Induction chemotherapy (IC) added to chemoradiation (CRT) in locally advanced cervical cancer (LACC) improves survival at the expense of adverse events (AEs), 99 % with IC/CRT vs 95 % CRT alone, 59 % vs 48 % G3/4 AEs. We investigated the impact of this on quality of life (QoL).</div></div><div><h3>Methods</h3><div>500 women with FIGO 2008 stage IB1 node positive, IB2, II, IIIB and IVA cervical carcinoma were randomised to CRT alone or IC (6 weeks carboplatin AUC2 paclitaxel 80mg/m²) followed by CRT. QoL questionnaires (EORTC QLQ-C30 v3, QLQ-CX24) were completed at baseline, D1 week 4 IC, D1 CRT, D1 week 3 CRT, 4 weeks post CRT and all follow up visits. Mixed modelling for repeated measures was used to compare the groups during trial treatment to 2 years follow up (adjusting for baseline).</div></div><div><h3>Results</h3><div>QoL (global health status, physical and social functioning) slightly worsened during IC and symptom experience slightly improved. Emotional functioning improved during IC.</div><div>Peripheral neuropathy was slightly worse with IC/CRT. Fatigue and nausea/vomiting worsened from baseline to week 4 IC whilst pain and diarrhoea improved, consistent with reported AEs. Over the whole period, mean differences for these symptoms between the treatment groups was small and not clinically significant and resolved by 12–18 months.</div><div>In all cases, mean score differences during trial treatment until 2 years post CRT showed only small differences (&lt;5 units) not meeting the threshold for clinical relevance.</div></div><div><h3>Conclusion</h3><div>IC added to CRT does not adversely impact QoL compared to CRT, either during IC, during CRT or later.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115375"},"PeriodicalIF":7.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction in surgical interventions in melanoma","authors":"Alexander C.J. van Akkooi ,&nbsp;Alexander M.M. Eggermont","doi":"10.1016/j.ejca.2025.115376","DOIUrl":"10.1016/j.ejca.2025.115376","url":null,"abstract":"<div><div>Melanoma surgery has evolved from elective lymph node dissection (ELND) to sentinel lymph node biopsy (SLNB) and wide local excision (WLE) margins have come down from 5 cm to nowadays 1 – 2 cm. Recent studies have illustrated the low frequency of residual tumour cells in WLE specimen, particularly for pT2 or lower tumours, where 97 % of patients cannot benefit from WLE. Moreover, a cohort of completely excised primary melanomas did not seem to have inferior clinical outcomes to those who did undergo WLE. Biomarkers, such as clinicopathological gene expression profilers (CP-GEP), can stratify high- and low-risk disease and make therapy decisions, in particular in clinical stage I/II melanoma and make sentinel lymph node biopsy (SLNB) largely redundant. Also SLNB needs to be reconsidered due to the lack of a clear overall survival benefit for adjuvant therapy in stage III. Moreover SLNB is redundant in stage IIB/C for decision making on adjuvant anti-PD1 therapy. Moreover the superiority of neo-adjuvant to salvage patients with macroscopic stage III over adjuvant therapy leads to sharp reduction of therapeutic lymph node dissections (TLND). Overall, the major impact of current developments is that SLNB might soon become obsolete and may be replaced by standard CP-GEP testing of the primary for clinical management, reduction of surgical interventions and simplification of follow up schedules in low risk patients. Thus, we are on the eve of a significant reduction in surgical interventions for melanoma that will come in the upcoming years.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115376"},"PeriodicalIF":7.6,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial","authors":"John M. Kirkwood ,&nbsp;Peter Mohr ,&nbsp;Christoph Hoeller ,&nbsp;Jean-Jacques Grob ,&nbsp;Michele Del Vecchio ,&nbsp;Jennifer Lord-Bessen ,&nbsp;Swetha Srinivasan ,&nbsp;Ayman Nassar ,&nbsp;Federico Campigotto ,&nbsp;Hannah Fairbanks ,&nbsp;Fiona Taylor ,&nbsp;Rachael Lawrance ,&nbsp;Georgina V. Long ,&nbsp;Jeffrey Weber","doi":"10.1016/j.ejca.2025.115371","DOIUrl":"10.1016/j.ejca.2025.115371","url":null,"abstract":"<div><h3>Background</h3><div>In the phase 3 CheckMate 76 K trial, adjuvant nivolumab significantly improved recurrence-free survival and distant metastasis-free survival versus placebo in patients with resected stage IIB/C melanoma. We report patient-reported outcomes from CheckMate 76 K.</div></div><div><h3>Methods</h3><div>Change from baseline to week 53 in health-related quality of life (HRQoL), as measured using the EORTC QLQ-C30 and EQ-5D-5L utility index and visual analog scale (VAS), was compared between treatment groups using linear mixed-effect models. Time to confirmed deterioration (TTCD) in HRQoL was assessed using Cox regression. Bother from side effects, as measured by the FACIT-GP5, was descriptively compared between treatment groups.</div></div><div><h3>Results</h3><div>There were no clinically meaningful differences in change from baseline between treatment groups in EORTC QLQ-C30 subscales, including global health status (GHS)/quality of life (QoL; least squares mean [LSM] difference: −1.3; 95 % confidence interval [CI]: −2.9, 0.4), and EQ-5D-5L utility index (LSM difference: −0.011; 95 % CI: −0.025, 0.004) and VAS (LSM difference: −1.3; 95 % CI: −2.6, 0.0). There was no difference in TTCD for nivolumab versus placebo in EORTC QLQ-C30 GHS/QoL (hazard ratio [HR]: 1.10; 95 % CI: 0.88, 1.36) or EQ-5D-5L utility index (HR: 1.10; 95 % CI: 0.86, 1.42); however, TTCD in EQ-5D-5L VAS was longer with placebo (HR: 1.92; 95 % CI: 1.39, 2.64). Proportions of patients reporting severe side effect bother (“quite a bit”/“very much”) were minimal (nivolumab: 1 %–4 %; placebo: 0 %–2 %).</div></div><div><h3>Conclusions</h3><div>Patients with resected stage IIB/C melanoma treated with adjuvant nivolumab demonstrated stable HRQoL and minimal bother from side effects.</div></div><div><h3>Clinical Trial Information</h3><div>NCT04099251</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115371"},"PeriodicalIF":7.6,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome” [Eur J Cancer 211 (2024) 114307]","authors":"Michele Bottosso ,&nbsp;Renata L. Sandoval ,&nbsp;Benjamin Verret ,&nbsp;Natalia Polidorio ,&nbsp;Olivier Caron ,&nbsp;Alessandra Gennari ,&nbsp;Brittany L. Bychkovsky ,&nbsp;Sophie H. Cahill ,&nbsp;Maria I. Achatz ,&nbsp;Valentina Guarneri ,&nbsp;Fabrice André ,&nbsp;Judy E. Garber","doi":"10.1016/j.ejca.2025.115370","DOIUrl":"10.1016/j.ejca.2025.115370","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115370"},"PeriodicalIF":7.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}